Skip to main content
. 2022 Oct 7;13:1021500. doi: 10.3389/fimmu.2022.1021500

Table 4.

Serum antibodies blocking GI.4 and GII.4 VLP binding to histo-blood group antigen at scheduled time points for each study group.

Time point
Blocking Assay Study group Parameter95% CI Day 1 Day 8 Day 29 Day 57 Day 183 Day 365
Anti-GI.4 rNV-2v/50 Geomean*
95% CI
62.3
45.6-100.6
837.0
843.7-2580.6
414.1
406.2-1200.9
349.1
331.6-866.2
152.1
136.0-351.9
109.9
83.4-247.1
GMFR
95% CI
ND
ND
13.4
14.1-50.0
6.6
5.5-20.7
5.6
4.7-14.0
2.4
2.0-5.3
1.8
1.3-3.3
rNV-2v/150 Geomean
95% CI
52.8
44.5-65.6
1627.2
1678.4-4432.4
569.7
567.1-1411.6
422.1
371.6-830.8
170.7
141.4-389.1
94.6
68.0-205.7
GMFR
95% CI
ND
ND
30.8
32.1-87.9
10.8
10.5-27.6
8.0
6.9-16.2
3.2
2.6-7.5
1.8
1.4-3.3
Placebo Geomean
95% CI
50.0
ND
50.0
ND
50.0
ND
50.0
ND
50.0
ND
51.9
47.1-58.2
GMFR
95% CI
ND
ND
1.0
ND
1.0
ND
1.0
ND
1.0
ND
1.0
0.9-1.2
Anti-GII.4 rNV-2v/50 Geomean
95% CI
115.4
94.6-200.5
1360.3
1088.6-3343.8
904.6
786.9-1497.1
744.6
652.8-1023.0
472.0
396.7-715.2
362.2
317.9-602.6
GMFR
95% CI
ND
ND
11.8
9.5-40.8
7.8
6.7-17.0
6.5
5.7-11.4
4.1
3.4-6.7
3.1
2.7-5.4
rNV-2v/150 Geomean
95% CI
121.3
96.8-260.6
2764.5
2432.6-4731.0
871.4
844.9-1520.7
703.4
657.3-1099.8
408.5
233.5-1186.8
286.2
262.0-637.1
GMFR
95% CI
ND
ND
22.8
16.7-62.8
7.2
5.3-16.4
5.8
4.7-10.1
3.4
2.8-5.8
2.4
1.9-3.6
Placebo Geomean
95% CI
102.4
84.5-177.7
107.5
55.2-273.1
101.5
76.0-196.0
104.9
83.8-187.6
113.6
96.8-203.
114.2
94.2-225.4
GMFR
95% CI
ND
ND
1.0
0.9-1.3
1.0
0.9-1.1
1.0
1.0-1.1
1.1
1.0-1.4
1.2
1.0-1.5

CI, confidence interval; Geomean, geometric mean antibody titre; GMFR, geometric mean fold-rise of the specific timepoint versus geomean at day 1 (= pre-vaccination); ND, not determined.

*Geometric mean values are expressed as half maximal inhibitory concentration/titer (IC50).